Twist Bioscience Corp vs Sprott Uranium Miners ETF — how do they compare? Twist Bioscience Corp trades at $124.01 (market cap $7.72B), while Sprott Uranium Miners ETF trades at $55.5. The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| TWST | URNM | |
|---|---|---|
Market Cap | $7.72B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $124.88 | $83.99 |
52-Week Low | $24.16 | $44.14 |
Enterprise Value | $7.65B | — |
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
URNM trades at $55.97, up 2.51% today, with a bullish technical signal driven by moving averages. The ETF focuses on uranium miners, benefiting from nuclear energy's resurgence. Recent news highlights significant government funding and AI-driven power demand as catalysts. Key support is at $55, with resistance at $56.
The outlook is positive due to structural uranium supply deficits and growing nuclear adoption, but risks include volatility from spot price swings and concentrated miner exposure. Analyst sentiment is mixed, with some favoring pure-miner exposure while others caution on valuation gaps versus underlying uranium prices.
Trailing returns across standard periods
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →